Skip to content

8:00 am Registration & Coffee Morning

8:50 am Chairperson Opening Remarks

A Review of the Current Landscape and Limitations of Phage and Phage-Derived Therapies

9:00 am Phage Lysins are Effective Antibiotic Alternatives

9:30 am The Implications of Fundamental Phage Biology on the Product Development Pipeline

10:00 am Economic Disincentives Are the Greatest Barrier to Phage and Phage-Derived Therapies

10:30 am Speed Networking & Morning Refreshments

Navigating the Regulatory Landscape of a Developing Therapy

11:30 am FDA Perspectives on Chemistry, Manufacturing, and Control for Bacteriophage Therapy Products

  • Scott Stibitz Chief, Laboratory of Mucosal Pathogens & Cellular Immunology, FDA

12:00 pm Early Phase Clinical Development of Bacteriophage

12:30 pm EU Considerations on Bacteriophage Therapy

1:00 pm Panel Discussion

1:30 pm Lunch & Networking

2:30 pm The Role of Bacteriophages as a Microbiome Modulator

Providing a Platform for Large-Scale Phage Manufacturing

3:00 pm Scalable Manufacturing, Formulation and Encapsulation of Bacteriophages for Targeted Delivery and Controlled Release

3:30 pm Afternoon Refreshments & Networking

4:00 pm Armata Pharmaceuticals GMP Manufacturing of Phage Drug Products

4:30 pm Platforms for Fast Purification of Food and Clinical Grade Bacteriophages and Their In-Process Analytics

4:50 pm Closing Remarks

5:00 pm End of Conference Day One & Evening Drinks Reception